Contract not negotiated.

Antioxidants have been studied for their abilities to combat reactive oxygen species in a multitude of conditions. This study aims to assess whether the botanical dietary supplement 'Halo Beauty Kiwi Booster' (HBKB), taken orally daily for 8 weeks, can assist with Acne vulgaris as well as skin hydration and quality of life for those with acne.

The study will be a 2-armed investigational trial with one group receiving botanical dietary supplement and one placebo group provided with the similar supplement vehicle. The trial will be double-blind, randomized, parallel-group study. The investigational group will receive the botanical dietary supplement 'Halo Beauty Kiwi Booster' (HBKB), to be taken orally daily for 8 weeks. Control group participants will receive the HBKB botanical dietary supplement vehicle as a placebo to be taken orally daily for 8 weeks.Participants will have their skin assessed

Inclusion Criteria:

• Adults 18-35 years of age able to provide consent to participate
• IGA of mild to moderately severe facial Acne Vulgaris (AV) at screening
• Potential participants with mild to moderately severe facial AV and with AV on their neck, shoulders, chest and/or back body surface areas may be included.

Exclusion Criteria:

• An Investigator Global Assessment IGA of severe facial, neck, back or truncal AV
• Diagnosis of a chronic inflammatory disease such as lupus, multiple sclerosis, cancer, Chron's disease or cancer
• Allergies to Astaxanthin (microalgae), Grape Seed Extract, Kiwi fruit or Kiwi extract, Pineapple fruit or extract (bromelain), Rosehip or Rosehip extract, Gooseberry, Rosehip, Grapes
• Secondary AV, such as occupational AV, steroid induced AV, or AV associated with endocrine disorders
• Having facial dermatosis that may interfere evaluations by IGA such as sunburn, eczema, psoriasis, erythematotelangectatic rosacea or seborrheic dermatitis
• Use of isotretinoin within 2 months
• Use of adapalene or tretinoin within 2 weeks
• Use of anti-biotics within 2 weeks
• Use of oral corticosteroids or androgens within 2 weeks
• Use of anticonvulsants
• Any subject who the PI deems unsuitable for any reason